PARP1 and ovarian carcinoma: In December 2014, the PARP inhibitor, Olaparib, was approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), after another drug for BRCA1/2 mutation-positive ovarian cancer [23].